Intrinsic Value of S&P & Nasdaq Contact Us

Amarin Corporation plc AMRN NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • IE • USD

SharesGrow Score
29/100
0/7 Pass
SharesGrow Intrinsic Value
$18.45
+26.8%
Analyst Price Target
$2.17
-85.1%
SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Amarin Corporation plc (AMRN) has a negative trailing P/E of -157.9, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 485.0 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -0.63%, forward earnings yield 0.21%. PEG 5.94.

Criteria proven by this page:

  • VALUE (10/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E -157.9); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -0.63%); analyst consensus target implies downside from the current price ($2.17, 85.1%); PEG > 2.0 means the stock is expensive even after accounting for growth (PEG 5.94).
  • Forward P/E 485.0 — analysts expect a return to profitability with estimated EPS of $0.03 for FY2026.
  • PEG Ratio 5.94 — above 2.0 suggests expensive relative to earnings growth.
  • Trailing Earnings Yield -0.63% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 0.21% as earnings recover.
  • Analyst consensus target $2.17 (-85.1% downside) — analysts see meaningful downside risk at the current price level.

Overall SharesGrow Score: 29/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score
29/100
SG Score
View full scorecard →
VALUE
10/100
Price-to-Earnings & upside
Proven by this page
FUTURE
16/100
Analyst consensus
→ Forecast
PAST
0/100
→ Income
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
~
MOAT
54/100
→ Income
~
GROWTH
48/100
→ Income
INCOME
10/100
→ Income

Valuation Snapshot — AMRN

Valuation Multiples
P/E (TTM)-157.9
Forward P/E485.0
PEG Ratio5.94
Forward PEG5.94
P/B Ratio13.34
P/S Ratio1.66
EV/EBITDA-11.0
Per Share Data
EPS (TTM)$-0.09
Forward EPS (Est.)$0.03
Book Value / Share$1.10
Revenue / Share$0.44
FCF / Share$0.02
Yields & Fair Value
Earnings Yield-0.63%
Forward Earnings Yield0.21%
Dividend Yield0.00%
SharesGrow IV$18.45 (+26.8%)
Analyst Target$2.17 (-85.1%)

Historical Valuation

Year P/E (TTM) PEG Ratio P/B Ratio P/S Ratio Dividend Yield
2016 -7.5 0.15 -71.61 4.99 -
2017 -16.0 0.41 -16.67 5.99 -
2018 -34.7 -0.62 26.56 17.65 -
2019 -324.3 3.90 12.07 17.09 -
2020 -97.8 3.42 2.81 2.87 -
2021 172.7 -1.22 2.00 2.29 -
2022 -4.6 0.00 0.82 1.31 -
2023 -5.8 0.14 0.62 1.12 -
2024 -2.4 -0.07 0.41 0.87 -
2025 -149.3 1.53 12.61 31.70 -

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year EPS (Diluted) Revenue Net Income Net Margin
2016 $-0.41 $130.08M $-86.35M -66.4%
2017 $-0.25 $181.1M $-67.87M -37.5%
2018 $-0.39 $229.21M $-116.45M -50.8%
2019 $-0.07 $429.76M $-22.65M -5.3%
2020 $-0.05 $614.06M $-18M -2.9%
2021 $0.02 $583.19M $7.73M 1.3%
2022 $-0.26 $369.19M $-105.8M -28.7%
2023 $-0.15 $306.91M $-59.11M -19.3%
2024 $-0.20 $228.61M $-82.18M -35.9%
2025 $-0.09 $182.75M $-38.8M -21.2%

Analyst Estimates

Year EPS (Avg) EPS Range Revenue (Avg) Revenue Range Analysts
2026 $0.03 $-0.01 – $0.07 $174.4M $168.27M – $180.52M 1
2027 $0.06 $-0.04 – $0.15 $176.59M $172.35M – $180.82M 1
2028 $0.07 $-0.03 – $0.17 $173.7M $160.87M – $186.54M 2
2029 $0.18 $0.16 – $0.20 $203.8M $188.74M – $218.86M 1
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message